[144] ASP Isotopes Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filing for ASP Isotopes Inc. (ASPI) reports a proposed sale of 8,438 shares of common stock through Independent Trading Group (ITG) on NASDAQ with an aggregate market value of $69,191.60. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and indicates the securities were granted as equity compensation. The filing shows 91,913,109 shares outstanding for the issuer and lists the approximate sale date as 09/08/2025. No securities were reported sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Small planned sale of equity compensation; immaterial to total share count and unlikely to affect market price materially.

The filing discloses a proposed sale of 8,438 shares valued at $69,191.60 against 91.9 million shares outstanding, representing roughly 0.009% of outstanding shares. The securities were acquired as a restricted stock award on 09/06/2024 and are to be sold through an identified broker on NASDAQ on 09/08/2025. No prior sales in the past three months are reported. From a financial-impact perspective, the announced amount is small relative to the company’s share base and appears to be a routine monetization of equity compensation rather than a signal of company-level stress.

Corporate Governance Expert

TL;DR: Standard Rule 144 notice for disposition of restricted stock; compliance and disclosure elements appear to be met.

The filer provides required Rule 144 information: acquisition date, nature of acquisition (restricted stock award), amount acquired, intended broker, and planned sale date. The statement affirms no undisclosed material adverse information. The filing includes no indications of accelerated insider selling or aggregated transactions, and no sales in the last three months were reported. Procedurally, this aligns with usual insider disposition disclosure obligations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Independent Trading Group (ITG) Inc. 33 Yonge Street Suite 420 Toronto A6 M5E 1G4	8438	69191.60	91913109	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/06/2024	Acquired as compensation -- Restricted Stock Award	Issuer			300000	09/06/2024	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ASPI's Form 144 disclose about the shares to be sold?

The filing discloses a proposed sale of 8,438 common shares through Independent Trading Group on NASDAQ with an aggregate market value of $69,191.60.

When were the shares being sold originally acquired according to the filing?

The shares were acquired on 09/06/2024 as a restricted stock award from the issuer, recorded as equity compensation.

How many total shares does ASP Isotopes report outstanding in the filing?

The filing lists 91,913,109 shares outstanding for the issuer.

Is there any record of securities sold by the filer in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

What is the approximate date of the planned sale?

The approximate date of sale is listed as 09/08/2025.